Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-25T06:59:08.491Z Has data issue: false hasContentIssue false
  • English
  • Français

Hypoprolactinaemic galactorrhoea in long-term methadone treatment

Published online by Cambridge University Press:  13 June 2014

Chimdi Uhoegbu ,
Michael Doran  and
John O'Connor
Chimdi Uhoegbu*
Affiliation:
The Drug Treatment Centre Board (DTCB), McCarthy Centre, 30-31 Pearse Street, Dublin 2, Ireland
Michael Doran
Affiliation:
The Drug Treatment Centre Board, McCarthy Centre, 30-31 Pearse Street, Dublin 2, Ireland
John O'Connor
Affiliation:
The Drug Treatment Centre Board, McCarthy Centre, 30-31 Pearse Street, Dublin 2, Ireland
*
*Correspondence Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Although hyperprolactinaemia is associated with galactorrhoea, galactorrhoea often occurs without any hyperprolactinaemia. This has been well established, and it has been documented in women prescribed/using methadone and other opiates. One case series described amenorrhoea and galactorrhoea in ‘female heroin addicts’, but it has not before been described in a patient with hypoprolactinaemia.

We report a case of a 30 year old non-pregnant, non-puerperal, opioid-dependent, HIV positive woman on long-term methadone maintenance programme, who presented with bilateral, milky nipple discharge, associated with painful breast lumps, but with serum prolactin levels below the normal range. She was not prescribed any other medications likely to have effect on the endocrine system. This case highlights the need for prescribers to be alert to the implications of long-term use of opioids.

Keywords

GalactorrhoeaHypoprolactinaemiaHyperprolactinaemiaOpioidsEndocrinology
Type
Case Reports
Information
Irish Journal of Psychological Medicine , Volume 28 , Issue 2 , June 2011 , pp. 100 - 102
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bennett, J, Whale, R. Galactorrhoea may be associated with methadone use. BMJ 2006; 332: 1071. doi:10.1136/bmj.332.7549.1071.CrossRefGoogle ScholarPubMed
2.Pelosi, MA, Sama, JC, Caterini, H, Kaminetzky, HA. Galactorrhea-amenorrhea syndrome associated with heroin addiction. Am J Obstet Gynecol 1974:118(7): 996–70.CrossRefGoogle ScholarPubMed
3. Wikipedia. The free dictionary. Available online at http://en.wikipedia.org/wiki/GalactorrhoeaGoogle Scholar
4.Leung, AKC, Pacuid, D. Diagnosis and Management of Galactorrhoea. Am Fam Physician, 2004.Google Scholar
5.Burns, M, Haddard, AR. Galactorrhoea: Assessment and Treatment Options. US Pharmacist, 1998.Google Scholar
6.Smith, RP. Gynecology in Primary Care. Baltimore: Williams and Wilkens, 1997.Google Scholar
7.Wong, J, Holdaway, I. Galactorrhoea causes, diagnosis and management. New Ethicals 1996; 33: 56–61.Google Scholar
8.Morley, JE. The Endocrinology of the opiates and opioid peptides. Metabolism 1981; 30: 95–209.CrossRefGoogle ScholarPubMed
9.Grossman, A. Brain opiates and neuroendocrine function. Clin Endocrinol Metab 1983; 12: 725–746. [Medline]CrossRefGoogle ScholarPubMed
10.Su, CF, Liu, MY, Li, MT. Intraventricular morphine produces pain relief, hypothermia, hyperglycemia and increased prolactin and growth hormone levels in patients with cancer pain. J Neurol 1987; 235: 195–108.[Cross Ref][Medline]CrossRefGoogle ScholarPubMed
11.Abbs, R, Verheist, J, Maeyaert, J, et al.Endocrine Consequences of Long Term Intrathecal Administration of Opioids. J Clin Endocrinol Metab 2000; 85: 2215–2222.CrossRefGoogle Scholar
12.Davies, PH. Drug-related hyperprolactinaemia. Adverse Drug React Toxicol Rev 1997; 16(2): 83–94.Google ScholarPubMed
13.Burns, M, Haddad, AR. Galactorrhoea: Assessment and Treatment Options. US Pharmacist, 1998.Google Scholar
14.Molitch, ME. Medication-Induced Hyperprolactinaemia. Mayo Clin Proc 2005; 80:1050–1057.CrossRefGoogle Scholar
15.Katz, E, Adashi, EY. Hyperprolactinaemia disorders. Clin Obstet Gynaecol 1990; 33(3): 622–639.CrossRefGoogle Scholar
16.Pena, KS, Rosenfeld, JA. Evaluation and treatment of galactorrhoea. Am Fam Phys 2001; 63(9 May)Google Scholar
17.Edge, DS, Segatore, M. Assessment and management of galactorrhoea. Nurse Pract 1993 Jun; 18(6): 35–6.CrossRefGoogle Scholar